OTCMKTS:MEDIF

MediPharm Labs Competitors

$0.38
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.37
Now: $0.38
$0.39
50-Day Range
$0.36
MA: $0.40
$0.58
52-Week Range
$0.35
Now: $0.38
$1.53
Volume487,730 shs
Average Volume1.04 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

MediPharm Labs (OTCMKTS:MEDIF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying MEDIF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to MediPharm Labs, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

MediPharm Labs (OTCMKTS:MEDIF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares MediPharm Labs and Abacus Health Products' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsN/AN/AN/AN/AN/A
Abacus Health ProductsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for MediPharm Labs and Abacus Health Products, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs03302.50
Abacus Health Products0000N/A

MediPharm Labs currently has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, equities research analysts plainly believe MediPharm Labs is more favorable than Abacus Health Products.

Profitability

This table compares MediPharm Labs and Abacus Health Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
Abacus Health ProductsN/AN/AN/A

Summary

MediPharm Labs beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Acreage and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcreageN/AN/AN/AN/AN/A
MediPharm LabsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Acreage and MediPharm Labs, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acreage01202.67
MediPharm Labs03302.50

Acreage presently has a consensus target price of $8.4333, indicating a potential upside of 204.45%. MediPharm Labs has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts clearly believe MediPharm Labs is more favorable than Acreage.

Profitability

This table compares Acreage and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcreageN/AN/AN/A
MediPharm LabsN/AN/AN/A

Summary

MediPharm Labs beats Acreage on 2 of the 3 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Applied Biosciences and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied BiosciencesN/AN/AN/AN/AN/A
MediPharm LabsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Applied Biosciences and MediPharm Labs, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Biosciences0000N/A
MediPharm Labs03302.50

MediPharm Labs has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts clearly believe MediPharm Labs is more favorable than Applied Biosciences.

Profitability

This table compares Applied Biosciences and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied BiosciencesN/AN/AN/A
MediPharm LabsN/AN/AN/A

Summary

MediPharm Labs beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Ayr Strategies and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
MediPharm LabsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Ayr Strategies and MediPharm Labs, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
MediPharm Labs03302.50

Ayr Strategies presently has a consensus target price of $34.8571, indicating a potential upside of 63.96%. MediPharm Labs has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts clearly believe MediPharm Labs is more favorable than Ayr Strategies.

Profitability

This table compares Ayr Strategies and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
MediPharm LabsN/AN/AN/A

Summary

Ayr Strategies beats MediPharm Labs on 2 of the 3 factors compared between the two stocks.

Can B (NASDAQ:CANB) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Profitability

This table compares Can B and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
MediPharm LabsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Can B and MediPharm Labs, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
MediPharm Labs03302.50

MediPharm Labs has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts clearly believe MediPharm Labs is more favorable than Can B.

Earnings and Valuation

This table compares Can B and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
MediPharm LabsN/AN/AN/AN/AN/A

Summary

MediPharm Labs beats Can B on 2 of the 2 factors compared between the two stocks.

Cansortium (OTCMKTS:CNTMF) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Cansortium and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CansortiumN/AN/AN/A
MediPharm LabsN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Cansortium and MediPharm Labs, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cansortium00103.00
MediPharm Labs03302.50

Cansortium currently has a consensus target price of $1.20, suggesting a potential upside of 18.81%. MediPharm Labs has a consensus target price of $1.3750, suggesting a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts plainly believe MediPharm Labs is more favorable than Cansortium.

Earnings and Valuation

This table compares Cansortium and MediPharm Labs' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CansortiumN/AN/AN/AN/AN/A
MediPharm LabsN/AN/AN/AN/AN/A

Summary

MediPharm Labs beats Cansortium on 2 of the 3 factors compared between the two stocks.


MediPharm Labs Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84flat$0.00N/A0.00Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77flat$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.22flat$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AYRSF
Ayr Strategies
1.4$21.26flat$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.53flat$0.00N/A0.00Gap Up
Cansortium logo
CNTMF
Cansortium
0.9$1.01flat$0.00N/A0.00
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.06flat$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.09flat$0.00N/A0.00Gap Down
CPHRF
Cipher Pharmaceuticals
1.2$1.08flat$0.00N/A0.00Decrease in Short Interest
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.22flat$0.00N/A0.00News Coverage
Gap Down
Cosmos logo
COSM
Cosmos
0.5$5.40flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.5$12.17flat$0.00N/A0.00Gap Up
Curaleaf logo
CURLF
Curaleaf
1.6$13.84flat$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.14flat$0.00N/A0.00Gap Down
EVIO logo
EVIO
EVIO
0.6$0.00flat$0.00N/A0.00News Coverage
Gap Down
Flower One logo
FLOOF
Flower One
0.4$0.22flat$0.00N/A0.00
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05flat$0.00N/A0.00News Coverage
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01flat$0.00N/A0.00Gap Up
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$28.20flat$0.00N/A0.00Gap Down
GTEC logo
GGTTF
GTEC
0.6$0.62flat$0.00N/A0.00Increase in Short Interest
Gap Up
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.88flat$0.00N/A0.00Gap Down
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01flat$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00News Coverage
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.68flat$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.22flat$0.00N/A0.00Gap Down
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.31flat$0.00N/A0.00Decrease in Short Interest
News Coverage
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.07flat$0.00N/A0.00Gap Up
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.40flat$0.00N/A0.00Decrease in Short Interest
Gap Down
KHTRF
Knight Therapeutics
1.2$4.20flat$0.00N/A0.00High Trading Volume
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01flat$0.00N/A0.00Increase in Short Interest
News Coverage
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.04flat$0.00N/A0.00Gap Down
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.29flat$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Down
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.76flat$0.00N/A0.00Increase in Short Interest
News Coverage
MJardin Group logo
MJARF
MJardin Group
1.1$0.07flat$0.00N/A0.00Gap Down
MYHI
Mountain High Acquisitions
0.5$0.02flat$0.00N/A0.00Gap Up
PHCEF
Pharmacielo
0.7$1.25flat$0.00N/A0.00Gap Down
Plus Products logo
PLPRF
Plus Products
1.1$0.52flat$0.00N/A0.00Decrease in Short Interest
Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00flat$0.00N/A0.00Gap Down
PCYN
Procyon
0.4$0.60flat$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Up
SANP
Santo Mining
0.5$0.01flat$0.00N/A0.00News Coverage
Gap Up
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.25flat$0.00N/A0.00Increase in Short Interest
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40flat$0.00N/A0.00News Coverage
TerrAscend logo
TRSSF
TerrAscend
1.7$10.02flat$0.00N/A0.00Analyst Report
Increase in Short Interest
Gap Down
The Flowr logo
FLWPF
The Flowr
1.5$0.25flat$0.00N/A0.00Gap Down
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.0$0.30flat$0.00N/A0.00Analyst Report
News Coverage
Gap Up
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.